CBX6 and chronic myelogenous leukemia, BCR-ABL1 positive: Tyrosine kinase inhibitor (TKI) treatment for CML patients, results in upregulation of CBX6 and CBX7 protein levels, and CML patients with low CBX6 and CBX7 levels respond better to treatment [31].